Julie Rubinstein has served as Adaptive Biotechnologies' President since February 2018 and assumed the additional role of Chief Operating Officer in April 2023. She joined Adaptive in April 2011 as head of Corporate and Business Development and served as Chief Business Officer from January 2016 to February 2018, and was part of the executive team that took the company public in 2019. Before Adaptive she held worldwide commercial development roles at Pfizer's Oncology division focused on cancer immunotherapy and various roles at Johnson & Johnson. She serves on the Boards of Trustees of The Valerie Fund and The Gift of Life. Ms. Rubinstein holds an MBA from Harvard Business School and dual undergraduate degrees from The Wharton School and Annenberg School of Communications at the University of Pennsylvania.